JP7343571B2 - マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 - Google Patents
マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 Download PDFInfo
- Publication number
- JP7343571B2 JP7343571B2 JP2021514292A JP2021514292A JP7343571B2 JP 7343571 B2 JP7343571 B2 JP 7343571B2 JP 2021514292 A JP2021514292 A JP 2021514292A JP 2021514292 A JP2021514292 A JP 2021514292A JP 7343571 B2 JP7343571 B2 JP 7343571B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- alkyl
- pharmaceutically acceptable
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023140718A JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671753P | 2018-05-15 | 2018-05-15 | |
| US62/671,753 | 2018-05-15 | ||
| PCT/US2019/032131 WO2019222157A1 (en) | 2018-05-15 | 2019-05-14 | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023140718A Division JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523241A JP2021523241A (ja) | 2021-09-02 |
| JP2021523241A5 JP2021523241A5 (cg-RX-API-DMAC7.html) | 2022-03-15 |
| JP7343571B2 true JP7343571B2 (ja) | 2023-09-12 |
Family
ID=66690981
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514292A Active JP7343571B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
| JP2021514291A Active JP7344959B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
| JP2023140718A Pending JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
| JP2023142664A Active JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514291A Active JP7344959B2 (ja) | 2018-05-15 | 2019-05-14 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
| JP2023140718A Pending JP2023164905A (ja) | 2018-05-15 | 2023-08-31 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
| JP2023142664A Active JP7656669B2 (ja) | 2018-05-15 | 2023-09-04 | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
Country Status (20)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023164905A (ja) * | 2018-05-15 | 2023-11-14 | フォアシー ファーマシューティカルズ ユーエスエー,インコーポレーテッド | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10532102B2 (en) * | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| DK4058437T3 (da) | 2019-11-14 | 2025-01-20 | Foresee Pharmaceuticals Usa Inc | Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf |
| JP2024520818A (ja) * | 2021-06-08 | 2024-05-24 | フォアシー ファーマシューティカルズ カンパニー リミテッド | 急性呼吸促迫症候群を処置するためのmmp阻害薬の使用 |
| KR20240019265A (ko) * | 2021-06-08 | 2024-02-14 | 포시 파마슈티컬스 컴퍼니 리미티드 | Mmp-12 억제제의 안전한 투여 |
| EP4198033A1 (en) | 2021-12-14 | 2023-06-21 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
| WO2023110473A1 (en) | 2021-12-14 | 2023-06-22 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040067996A1 (en) | 2002-10-04 | 2004-04-08 | James Sheppeck | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| JP2008510701A (ja) | 2004-08-19 | 2008-04-10 | クエスト ファーマシューティカル サーヴィシーズ | マクロファージエラスターゼの阻害剤としての5−[3−(4−ベンジルオキシフェニルチオ)−フラ−2−イル]−イミダゾリジン−2,4−ジオン及び類似体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2482618A1 (fr) | 1980-05-16 | 1981-11-20 | Inst Corps Gras Iterg | Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application |
| AU1817700A (en) | 1998-12-31 | 2000-07-24 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6352976B1 (en) | 1998-12-31 | 2002-03-05 | Aventis Pharmaceuticals Inc. | Selective inhibitors of MMP-12 |
| AU4882101A (en) | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
| SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| MXPA03008180A (es) * | 2001-03-15 | 2003-12-12 | Astrazeneca Ab | Inhibidores de metaloproteinasa. |
| ATE445400T1 (de) | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
| EP1394159A1 (fr) | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| JP5357365B1 (ja) | 2011-12-21 | 2013-12-04 | パナソニック株式会社 | データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法 |
| SG11202011318QA (en) * | 2018-05-15 | 2020-12-30 | Foresee Pharmaceuticals Usa Inc | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
-
2019
- 2019-05-14 SG SG11202011318QA patent/SG11202011318QA/en unknown
- 2019-05-14 KR KR1020207035504A patent/KR102861502B1/ko active Active
- 2019-05-14 FI FIEP19731374.5T patent/FI3793992T3/fi active
- 2019-05-14 PL PL19728197.5T patent/PL3793995T3/pl unknown
- 2019-05-14 ES ES19731374T patent/ES2984594T3/es active Active
- 2019-05-14 US US17/055,459 patent/US11739080B2/en active Active
- 2019-05-14 TW TW108116631A patent/TWI827601B/zh active
- 2019-05-14 DK DK19728197.5T patent/DK3793995T3/da active
- 2019-05-14 CN CN202411619226.XA patent/CN119462623A/zh active Pending
- 2019-05-14 FI FIEP19728197.5T patent/FI3793995T3/fi active
- 2019-05-14 EP EP19731374.5A patent/EP3793992B1/en active Active
- 2019-05-14 CN CN201980047375.4A patent/CN112424192B/zh active Active
- 2019-05-14 EP EP19728197.5A patent/EP3793995B1/en active Active
- 2019-05-14 US US17/055,483 patent/US12258335B1/en active Active
- 2019-05-14 HU HUE19731374A patent/HUE066627T2/hu unknown
- 2019-05-14 PT PT197281975T patent/PT3793995T/pt unknown
- 2019-05-14 TW TW108116632A patent/TWI798435B/zh active
- 2019-05-14 CA CA3100319A patent/CA3100319A1/en active Pending
- 2019-05-14 ES ES19728197T patent/ES2978192T3/es active Active
- 2019-05-14 AU AU2019270975A patent/AU2019270975B2/en active Active
- 2019-05-14 TW TW112115526A patent/TWI895726B/zh active
- 2019-05-14 CN CN201980047333.0A patent/CN112424186A/zh active Pending
- 2019-05-14 WO PCT/US2019/032127 patent/WO2019222154A1/en not_active Ceased
- 2019-05-14 AU AU2019269409A patent/AU2019269409B2/en active Active
- 2019-05-14 KR KR1020257002624A patent/KR20250021604A/ko active Pending
- 2019-05-14 US US16/411,336 patent/US20190352288A1/en not_active Abandoned
- 2019-05-14 LT LTEPPCT/US2019/032131T patent/LT3793995T/lt unknown
- 2019-05-14 SI SI201930733T patent/SI3793995T1/sl unknown
- 2019-05-14 SG SG11202011316RA patent/SG11202011316RA/en unknown
- 2019-05-14 EP EP24150920.7A patent/EP4349332B1/en active Active
- 2019-05-14 BR BR112020023269-6A patent/BR112020023269A2/pt unknown
- 2019-05-14 US US16/411,402 patent/US10851089B2/en active Active
- 2019-05-14 JP JP2021514292A patent/JP7343571B2/ja active Active
- 2019-05-14 HU HUE19728197A patent/HUE066619T2/hu unknown
- 2019-05-14 DK DK19731374.5T patent/DK3793992T3/da active
- 2019-05-14 CA CA3100320A patent/CA3100320A1/en active Pending
- 2019-05-14 EP EP24150915.7A patent/EP4335499A3/en active Pending
- 2019-05-14 MY MYPI2020005983A patent/MY199200A/en unknown
- 2019-05-14 JP JP2021514291A patent/JP7344959B2/ja active Active
- 2019-05-14 KR KR1020207035503A patent/KR102761591B1/ko active Active
- 2019-05-14 WO PCT/US2019/032131 patent/WO2019222157A1/en not_active Ceased
- 2019-05-14 PT PT197313745T patent/PT3793992T/pt unknown
-
2023
- 2023-07-06 US US18/347,674 patent/US12215096B2/en active Active
- 2023-08-31 JP JP2023140718A patent/JP2023164905A/ja active Pending
- 2023-09-04 JP JP2023142664A patent/JP7656669B2/ja active Active
-
2024
- 2024-01-18 AU AU2024200323A patent/AU2024200323B2/en active Active
- 2024-12-17 US US18/983,692 patent/US20250115590A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040067996A1 (en) | 2002-10-04 | 2004-04-08 | James Sheppeck | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| JP2008510701A (ja) | 2004-08-19 | 2008-04-10 | クエスト ファーマシューティカル サーヴィシーズ | マクロファージエラスターゼの阻害剤としての5−[3−(4−ベンジルオキシフェニルチオ)−フラ−2−イル]−イミダゾリジン−2,4−ジオン及び類似体 |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY STN Online, 2008, RN 1061319-03-6,2008年,RN 1061319-03-6 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023164905A (ja) * | 2018-05-15 | 2023-11-14 | フォアシー ファーマシューティカルズ ユーエスエー,インコーポレーテッド | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023164905A (ja) | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 | |
| JP5898230B2 (ja) | S−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物 | |
| RU2820540C2 (ru) | Ингибиторы матриксной металлопротеиназы (mmp) и способы их применения | |
| HK40050772B (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050772A (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| JP7653986B2 (ja) | マトリックスメタロプロテイナーゼ(mmp)阻害剤及びその使用方法 | |
| HK40107395A (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050775B (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| HK40050775A (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220307 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230531 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230801 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230831 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7343571 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |